|Funding||CRUK and HOVON|
ReBeL is a prospective, randomised, multicentre, international phase II trial (phase I is not being conducted in the UK). ReBeL has two experimental arms; lenalidomide and rituximab versus lenalidomide, rituximab and bendamustine; the most promising of which will be taken on to a large randomised phase III trial. Patients will receive 6 induction cycles of lenalidomide in combination with rituximab with or without bendamustine, followed by 2 years of maintenance treatment rituximab, once every three months. Patients will be followed up every 6 months thereafter, up to 8 years post registration.